Musto et al identified factors associated with a hematologic response to darbepoetin alpha in a patient with low or intermediate risk myelodyplastic syndrome (MDS). These can help distinguish responders from nonresponders. The authors are from IRCCS Casa Sollievo della Sofferenza Hospital, University of Ferrara, University of Genova, Leonardo da Vinci Institute and S. Martino Hospital in Italy.

To read more or access our algorithms and calculators, please log in or register.